Mode
Text Size
Log in / Sign up
Phase 4 Completed N=60 Randomized Triple-blind Treatment

Improving Sleep and Psychological Functioning in People With Depression and Insomnia

Sleep Initiation and Maintenance Disorders · Depression
Source: ClinicalTrials.gov NCT00247624 ↗
Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcomePrimary: Daily Living and Role Functioning (DLRF) Basis-32 Subscale Ratings — 0.81; 1.2 units on a scale
◆ Published Evidence
Highly cited
235citations · ~15 / year
Insomnia severity is an indicator of suicidal ideation during a depression clinical trial.
Sleep medicine · 2010 · Open access · Likely link

Summary

This study will evaluate the safety and effectiveness of treatment with both a sleeping pill and antidepressant medication in improving sleep and psychological functioning in people with depression and insomnia.

Linked Publications (5)

  • Insomnia severity is an indicator of suicidal ideation during a depression clinical trial.
    Sleep medicine · 2010 · 235 citations · Open access · Likely link
  • Comparison of actigraphy with polysomnography and sleep logs in depressed insomniacs.
    Journal of sleep research · 2012 · 181 citations · Open access · Likely link
  • Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2010 · 99 citations · Open access · Likely link
  • Objective vs. subjective measurements of sleep in depressed insomniacs: first night effect or reverse first night effect?
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2012 · 71 citations · Open access · Likely link
  • Dissection of the factors driving the placebo effect in hypnotic treatment of depressed insomniacs.
    Sleep medicine · 2011 · 22 citations · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Daily Living and Role Functioning (DLRF) Basis-32 Subscale Ratings
0.81; 1.2
PRIMARY
Relation to Self/Others (RSO) Basis-32 Subscale Ratings
0.74; 1.04
PRIMARY
Quality of Life Ratings, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
50.2; 46.9
SECONDARY
Insomnia Severity Index (ISI)
21.1; 20.2

Eligibility Criteria

Inclusion Criteria

  • Score of greater than 10 on the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire (PRIME-MD-PHQ) telephone screen
  • Diagnosis of major depressive episode based on the Structured Clinical Interview for DSM-IV (SCID)
  • Score of greater than 20 on the Hamilton Rating Scale for Depression
  • Meets research diagnostic criteria for insomnia disorder at least 4 nights per week
  • Reported mean sleep latency greater than 30 minutes and mean sleep efficiency less than 85%
  • Suitable for outpatient treatment

Exclusion Criteria

  • Use of any psychotropic medications within 2 weeks of initial screening
  • Bipolar disorder, schizophrenia, psychotic depression, or any other psychotic disorder
  • Uncontrolled asthma or chronic obstructive pulmonary disease
  • Chronic pain that may be a significant sleep-disturbing factor
  • Uncontrolled thyroid disease
  • Poorly controlled diabetes mellitus
  • Poorly compensated congestive heart failure
  • Currently taking lipophilic beta blockers, opioids, glucocorticoids, theophylline, or other medications known to interfere with sleep
  • History of intolerance or treatment resistance to either fluoxetine or eszopiclone
  • Inability to abstain from taking any psychotropics other than the study medications during the course of the protocol, including sedating antihistamines
  • Use of any herbal or naturopathic treatments for sleep or mood (i.e., St. John's wort, melatonin, kava kava, valerian root, etc.)
  • Currently undergoing behavioral, cognitive-behavioral, or interpersonal therapy
  • Pregnant or breastfeeding
  • Agrees to use an effective form of contraception for the duration of the study
  • Uncontrolled symptoms of menopause, including hot flashes
  • Uncontrolled hypertension (systolic blood pressure consistently greater than 140 mm Hg, diastolic blood pressure consistently greater than 90 mm Hg)
  • Diagnosis of sleep apnea, periodic limb movement disorder, or restless leg syndrome
  • Reports habitual bedtime earlier than 9 PM or later than 1 AM more than 2 times per week
  • Reports habitual rising time later than 9 AM more than 2 times per week
  • Body mass index greater than 30
  • Consumes more than 3 alcoholic beverages per day
  • Consumes more than 4 caffeinated beverages per day
  • Habitual smoking between 11 PM and 7 AM
  • Use of illicit drugs
  • Score greater than 24 on the Mini Mental State Examination
  • Determined to be incompetent
  • Determined to be at imminent risk for suicide
  • More than 5 lifetime SCID diagnoses of major depressive episodes
  • More than 3 failed antidepressant trials during the current episode of depression, as determined by the Antidepressant Treatment History Form
  • A course of electroconvulsive therapy during the present depressive episode
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00247624) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search